PPAR dual agonist

Xu X. et al., 2005. Quantitative determination of a novel dual PPAR aly agonist using online turbulent flow extraction with liquid chromatography-tandem mass spectrometry. J Chromatogr B 814 29. 

Kasuga, J., Yamasaki, D., Araya, Y, Nakagawa, A., Makishima, M., Doi, T., Hashimoto, Y, Miyachi, H. Design, synthesis, and evaluation of a novel series of alpha-substituted phenylpropanoic acid derivatives as human peroxisome proliferator-activated receptor (PPAR) alpha/ delta dual agonists for the treatment of metabolic syndrome. Bioorg. Med. Chem. 2006, 14, 8405-8414. 

PPAR proliferator-activated receptor Dual PPARo/y dual agonist... 

Workers at Lilly prepared the oxazole-containing, dual PPAR ot/y agonist 23, through Robinson-Gabriel cyclodehydration of ketone 22 with acetic anhydride and sulfuric acid in refluxing ethyl acetate. ... 

Xu, X., Yana, K. X., Songa, H., and Loa, M. W. (2005a). Quantitative determination of a novel dual PPAR a/y agonist using on-line turbulent-flow extraction with liquid chromatography-tandem mass spectrometry. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 814 29-36. 

H. Song, K. Yan, X. Xu, and M. W. Lo, Quantitative determination of MK-0767, a dual alpha/gamma peroxisome prohferators-activated receptor (PPAR) agonist, in human plasma by liquid chromatography-tandem mass spectrometry, J. Chromatogr. B 810 (2004), 7-13. 

Egr-1 transcription factor, which was suggested as a candidate biomarker for the carcinogenic effect of dual-acting PPAR agonists. As the specific PPARy agonist rosiglitazone causes cancer promotion rather than initiation, PPARa activation may have relevance for urothelial cancer initiation. [58 ]... 

---